Paper Details

  1. Home
  2. Paper Details

Revealing mechanism of Methazolamide for treatment of ankylosing spondylitis based on network pharmacology and GSEA.

Author: GaoPing, LiangWeiqiang, LiuQiang, SunTao, WangManzhi, YanXinfeng

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates the role of carbonic anhydrase 1 (CA1) in ankylosing spondylitis (AS) and the mechanism of action of methazolamide, a CA inhibitor, in treating AS. Methazolamide has been shown to be effective in treating AS, likely by reducing inflammation. The study used computer modeling to identify potential targets of methazolamide and found that it may act by inhibiting specific genes and pathways involved in inflammation. Further research is needed to confirm these findings.
Paper Details　
Original Abstract of the Article :
Methazolamide is a carbonic anhydrase (CA) inhibitor with satisfactory safety. Our previous studies have demonstrated the elevation of CA1 expression and the therapeutic effect of Methazolamide in Ankylosing spondylitis (AS). In this study, we explored the pathogenic role of CA1 and the pharmacologi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505193/

データ提供：米国国立医学図書館（NLM）

Methazolamide: A Promising Therapeutic Target for Ankylosing Spondylitis

We're embarking on a journey into the complex world of rheumatology, specifically examining the potential of methazolamide, a carbonic anhydrase (CA) inhibitor, for treating ankylosing spondylitis (AS). This study delves into the pathogenic role of CA1 in AS and explores the pharmacological mechanisms of methazolamide in targeting this enzyme. The research utilizes network pharmacology and gene set enrichment analysis (GSEA) to investigate the therapeutic potential of methazolamide in AS.

Methazolamide: A Novel Approach to Ankylosing Spondylitis Treatment

This study reveals the potential of methazolamide as a therapeutic target for AS, highlighting its ability to modulate inflammatory pathways and potentially improve clinical outcomes. The research, like a compass guiding us through the intricate landscape of AS treatment, provides valuable insights into the therapeutic mechanisms of this drug.

Understanding Ankylosing Spondylitis

Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints. This study emphasizes the importance of exploring novel therapeutic targets, like CA1, for managing this challenging condition.

Dr.Camel's Conclusion

This research, like a well-traveled oasis in the desert of AS research, unveils the potential of methazolamide as a promising therapeutic agent. This study offers a beacon of hope for individuals suffering from AS, highlighting the need for further investigation into this drug's efficacy and safety.

Date :
  1. Date Completed 2023-09-18
  2. Date Revised 2023-11-19
Further Info :

Pubmed ID

37717047

DOI: Digital Object Identifier

PMC10505193

Related Literature

Article Analysis
・Effects of methazolamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.